Estimated lifetime harms and benefits of continuing biennial prostate cancer screening in older men by comorbidity group
BACKGROUND: Prostate-specific antigen (PSA) screening prevents prostate cancer death but also leads to overdiagnosis-diagnosis that would not occur during a man's lifetime without screening-particularly in older men and those with life-limiting comorbidities. Modern screening approaches attempt to mitigate overdiagnosis in older men by using a higher PSA threshold for further evaluation using magnetic resonance imaging (MRI), and discontinuing screening in men with low PSA levels. However, long-term harms and benefits have not been estimated. METHODS: Two microsimulation models estimated lifetime harms and benefits of modern screening approaches in men who were screened biennially at ages 50-70 years, remained undiagnosed with prostate cancer at age 72 years, and faced varying risks of competing mortality based on previously estimated comorbidity-adjusted life tables. RESULTS: By using a PSA threshold of 6.5 ng/mL for evaluation with MRI and MRI-targeted biopsy, estimated ratios of overdiagnoses to cancer deaths prevented were similar when all men aged 70 years or older continued screening versus when only in men with PSA levels ≥ 3.0 ng/mL continued screening. For men with no comorbidities, this ratio increased from 2.7-3.1 at age 72 years to 4.5-5.1 at age 76 years. For men with severe comorbidities, this ratio increased from 9.6-10.2 at ages 72 to 11.3-12.6 at 76 years. CONCLUSIONS: Even using modern approaches, the ratio of overdiagnoses per cancer death prevented increases with age and is at least double in men with severe life-limiting comorbidities compared with age-matched men with no comorbidities. The current results can help inform patients and providers about when to stop PSA screening.
Authors
- Lukas Owens (ORCID: https://orcid.org/0000-0002-5149-5379)
- Louise Christie Walter (ORCID: https://orcid.org/0000-0002-9642-6238)
- Krithika Suresh (ORCID: https://orcid.org/0000-0001-7785-3536)
- Jeremy M. G. Taylor (ORCID: https://orcid.org/0000-0003-2791-1229)
- Roman Gulati (ORCID: https://orcid.org/0000-0002-7592-6567)
- Ruth Etzioni (ORCID: https://orcid.org/0000-0002-9164-6370)
- Alex Tsodikov
- Sarah P. Psutka (ORCID: https://orcid.org/0000-0002-4207-7490)
Institutions
- University of California, San Francisco (US)
- University of Washington (US)
- University of Michigan (US)
- Fred Hutch Cancer Center (US)
Publication Details
- Journal
- Cancer
- Published
- 2026-11-12
- DOI
- https://doi.org/10.1002/cncr.70620
- Citations
- 1
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 5.16
Funders
- Fred Hutchinson Cancer Research Center
- National Institutes of Health
- National Cancer Institute